End of April the General Assembly High-Level Interactive Dialogue on Tackling AMR took place as a virtual event. To raise global attention, a Call…
US pharma company Pfizer acquired US-based biotech company Amplyx Pharmaceuticals for an undisclosed sum. The deal provides Pfizer with a pipeline led by phase…
CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive funding to develop an innovative rapid diagnostic for…
US-based X-Biotix Therapeutics, focused on antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, will suspend its current antibacterial research efforts. The company will instead focus on…
CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa,…
The WHO has published their updated analysis for the clinical and preclinical antibacterial product pipeline in 2020. The review addresses antibacterial drug candidates against…
Swiss BioVersys has received €20m from the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections. The venture debt…